IL6 and chronic kidney disease: Furthermore, the application of ziltivekimab, a human monoclonal antibody targeting IL‐6 in high‐risk CV patients with chronic kidney disease and an increased inflammatory state in the phase‐2 RESCUE trial (Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL‐6 Inhibition) resulted in significant reductions of several pro‐inflammatory and prothrombotic biomarkers, including an over 90% reduction in hsCRP at the highest dose tested.76